| Literature DB >> 25548593 |
Jincai Hou1, Jun Wang2, Chengren Lin1, Jianhua Fu1, Jianxun Ren1, Lei Li1, Hao Guo1, Xiao Han1, Jianxun Liu1.
Abstract
We compared the circulating microRNA profiles of Qi-stagnation (QSB) and Qi-deficiency (QDB) in coronary heart disease (CHD) patients with blood stasis syndrome. Twenty-nine CHD patients were divided into QSB group and QDB group. The analysis was carried out through comparing their circulating microRNA profiles and the following bioinformatics analysis. The number of differential miRNAs in QDB group was much more than that in QSB group. Functional annotations of the differentially expressed miRNAs target genes in the QSB group and QDB group were, respectively, related to regulation of cellular component organization, regulation of glucose metabolic process, and so forth and protein kinase cascade, phosphate metabolic process, and so forth. KEGG pathway analysis showed that the process Qi-deficiency was associated with phagocytosis including endocytosis and mTOR signaling pathway. Specifically, pathway of cell adhesion molecules played the crucial role in the pathological process of Qi-stagnation, with a unique upregulation except for pathways associated with cancer signal. MicroRNA-gene-net analysis indicated that let-7c, miR-4487, miR-619, miR-8075, miR-6735, and miR-32-5p and miR-17-5p, miR-130a, and miR 320 family had the most important and extensive regulatory function for Qi-stagnation syndromes and Qi-deficiency syndromes, respectively. Differentially expressed miRNAs and concerned pathways suggest different molecular mechanisms that may mediate the pathological process of QSB and QDB syndromes.Entities:
Year: 2014 PMID: 25548593 PMCID: PMC4273468 DOI: 10.1155/2014/926962
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Demographic characteristics of CHD patients with QSB and QDB syndrome.
| QSB ( | QDB ( | |
|---|---|---|
| Demographics: | ||
| Mean age (years) | 65.43 ± 9.5 | 66.55 ± 11.7 |
| Sex (Male) | 4 | 8 |
| Heart rate (BPM) | 83.2 ± 6.8 | 77.8 ± 10.7 |
| Blood pressure (SBP/DBP) | 144 ± 12.1/90.6 ± 11.3 | 140.5 ± 5.23/81.8 ± 4.1 |
| Body mass index (kg/m2), mean ± SE | 27.9 ± 0.6 | 26.2 ± 0.85 |
| Comorbid conditions: | ||
| Hypertension | 3 (42) | 15 (68) |
| Diabetes mellitus | 1 (14) | 4 (18) |
| Hyperlipidemia | 1 (14) | 4 (18) |
| Current smoking | 4 (57) | 13 (59) |
| Alcohol | 2 (28) | 6 (27) |
| Prehospital medications: | ||
| Statins | 5 (71) | 20 (90) |
| Beta blocker | 1 (14) | 5 (22) |
| Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker | 2 (28) | 8 (36) |
| Calcium channel blocker | 2 (28) | 6 (27) |
| Aspirin | 3 (43) | 9 (41) |
| Nitroglycerin | 3 (43) | 7 (32) |
Figure 1(a) Section of upregulated differentially miRNAs overlapping and nonoverlapping in QSB and QDB groups. (b) Section of downregulated differentially miRNAs overlapping and nonoverlapping in QSB and QDB groups. (c) Real time qRT-PCR validation of the microarray results: microarray results compared to qRT-PCR results relative to the OC. The obvious upregulated or downregulated miRNAs in QSB and QDB groups from microarray data (FDR P < 0.05; fold change > 1.5) were randomly selected. Expression changes are depicted as log2 fold change (x-axis). miRNAs symbols are shown on the other side of the column.
Figure 2(a) Section of overlapping and nonoverlapping upregulated functional annotations from the differentially expressed miRNAs target genes. (b) Section of overlapping and nonoverlapping downregulated functional annotations from the differentially expressed miRNAs target genes. (c) Bar graphs showed the most obvious upregulated and downregulated functional annotations of QSB group. (d) Bar graphs showed the most obvious upregulated and downregulated functional annotations of QDB group. Expression changes are depicted as P value (x-axis). GO symbols are shown on the other side of the column.
Figure 3(a) Venn diagram showed overlapping and nonoverlapping upregulated pathways in QSB and QDB groups. (b) Venn diagram showed overlapping and nonoverlapping downregulated pathways in QSB and QDB groups. (c) The microRNA-gene-network diagram of QSB. (d) The microRNA-gene-network diagram of QDB. Red squares represent upregulated miRNAs and the blue squares represent downregulated miRNAs. Blue rounds represent the target genes of their connected miRNAs. Black lines represent the regulatory relation between miRNAs and their target genes.
Upregulated pathways in patients with QSB syndrome.
| Path_ID | Path_name | Count | % |
| FDR |
|---|---|---|---|---|---|
| hsa05215 | Prostate cancer | 16 | 1.394943 | 2.63 | 0.020708 |
| hsa05214 | Glioma | 12 | 1.046207 | 0.00128 | 0.065618 |
| hsa05218 | Melanoma | 12 | 1.046207 | 0.003441 | 0.128043 |
| hsa04514 | Cell adhesion molecules (CAMs) | 17 | 1.482127 | 0.006066 | 0.175925 |
| hsa05222 | Small cell lung cancer | 11 | 0.959024 | 0.030494 | 0.42138 |
| hsa05223 | Non-small cell lung cancer | 8 | 0.697472 | 0.043989 | 0.510943 |
| Path_ID | Path_name | Count | % |
| FDR |
|---|---|---|---|---|---|
| hsa04144 | Endocytosis | 41 | 0.245627 | 5.65 | 9.66 |
| hsa04360 | Axon guidance | 28 | 0.167745 | 1.84 | 0.00157 |
| hsa05212 | Pancreatic cancer | 15 | 0.089863 | 0.003962 | 0.126948 |
| hsa04010 | MAPK signaling pathway | 36 | 0.215672 | 0.01223 | 0.259629 |
| hsa05220 | Chronic myeloid leukemia | 14 | 0.083873 | 0.014293 | 0.239301 |
| hsa04070 | Phosphatidylinositol signaling system | 13 | 0.077882 | 0.029505 | 0.400777 |
| hsa04810 | Regulation of actin cytoskeleton | 28 | 0.167745 | 0.041864 | 0.485632 |
| hsa04012 | ErbB signaling pathway | 14 | 0.083873 | 0.043572 | 0.469973 |
| Path_ID | Path_name | Count | % |
| FDR |
|---|---|---|---|---|---|
| hsa04012 | ErbB signaling pathway | 18 | 1.880878 | 1.15 | 0.001671 |
| hsa05214 | Glioma | 14 | 1.462905 | 6.91 | 0.00503 |
| hsa04910 | Insulin signaling pathway | 21 | 2.194357 | 1.33 | 0.006429 |
| hsa04510 | Focal adhesion | 27 | 2.821317 | 1.39 | 0.005062 |
| hsa04730 | Long-term depression | 13 | 1.358412 | 6.98 | 0.016838 |
| hsa05220 | Chronic myeloid leukemia | 13 | 1.358412 | 0.001496 | 0.030734 |
| hsa04720 | Long-term potentiation | 12 | 1.253918 | 0.002133 | 0.038212 |
| hsa04722 | Neurotrophin signaling pathway | 17 | 1.776385 | 0.002769 | 0.039679 |
| hsa04150 | mTOR signaling pathway | 10 | 1.044932 | 0.003329 | 0.043298 |
| hsa05212 | Pancreatic cancer | 12 | 1.253918 | 0.003394 | 0.04052 |